Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Rhea-AI Summary

Zealand Pharma A/S (NASDAQ: ZEAL) announced share transactions involving managerial personnel and closely associated individuals. This release states that relevant transactions have been conducted in Zealand's shares or related securities, consistent with corporate governance. The company, based in Copenhagen and Boston, specializes in peptide-based medicines, with two products on the market and a robust pipeline. Zealand recently received FDA approval for Zegalogue, the first glucagon analogue for severe hypoglycemia in diabetes patients.

Positive

• FDA approval for Zegalogue enhances market potential.
• Strong pipeline with three candidates in late-stage development.
• Collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals expand growth opportunities.

Negative

• None.

Company announcement – No. 30 / 2021

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, DK and Boston, MA, U.S., May 14, 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached files.

# # #

About Zealand Pharma A/S 

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and has received FDA approval for Zegalogue, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com

Attachments

• 37_210512_Notification_EDulac_rsu
• 38_210512_Notification_ASteensberg_rsu
• 39_210512_Notification_IMøller_rsu
• 40_210512_Notification_GRasmussen_rsu
• 41_210512_Notification_JStenvang_rsu
• 42_210512_Notification_LGjelstrup_rsu
• 43_210512_Notification_FBeck_rsu

FAQ

What share transactions were reported by Zealand Pharma (ZEAL) on May 14, 2021?

Zealand Pharma reported transactions in its shares and related securities conducted by its managerial personnel and their closely associated individuals.

What is the significance of Zealand Pharma's FDA approval for Zegalogue?

The FDA approval for Zegalogue positions Zealand Pharma to address severe hypoglycemia in diabetes patients, expanding its product offerings.

How many drug candidates does Zealand Pharma have in clinical development?

Zealand Pharma has more than 10 drug candidates in clinical development, with two already on the market.

What are Zealand Pharma's collaborations with major pharmaceutical companies?

Zealand has licensing collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals, which could benefit more patients with its peptide-based medicines.